title: Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes:  results of the ONTARGET trial.
abstract: BACKGROUND
  A recent study suggested that addition of a direct renin inhibitor to either an angiotension-converting enzyme (ACE) inhibitor (ACEi) or an angiotensin receptor blocker (ARB) may increase stroke risk in people with diabetes and renal disease.
  
  
  METHODS
  We examined the effects of addition of an ACE inhibitor (ramipril) to an ARB (telmisartan) for a mean follow-up of 56 months in people with diabetes [n = 9628, mean age 66 years, baseline blood pressure 144/82 mmHg, BMI 29 kg/m², estimated glomerular filtration rate (eGFR) 73 ml/min, and urine albumin 11 mg/mmol] who participated in the ONTARGET trial, divided by those with (n = 3163) and without (n = 6465) nephropathy. We compared participants on monotherapy with either ramipril or telmisartan with those on dual therapy.
  
  
  RESULTS
  SBP decreased more with dual over monotherapy (-7.1 vs. -5.3 mmHg, P < 0.0001) and the same number of strokes occurred (1.19 vs. 1.22 per 100 patient-years; hazard ratio 0.99, 95% confidence interval 0.82-1.20). Stroke rate was higher in participants with than those without diabetic nephropathy (1.5 vs. 1.0 per 100 patient-years), but effects of dual-therapy vs. monotherapy were not different in either subgroup (1.59 vs. 1.55 and 1.01 vs. 1.08 per 100 patient-years; P value for interaction = 0.60). Other cardiovascular and kidney outcomes (dialysis or doubling of serum creatinine) did not differ between dual-therapy and monotherapy in subgroups, but adverse events, namely acute dialysis, hyperkalemia and hypotension, tended to be more frequent with dual therapy,
  
  
  CONCLUSIONS
  A combination of ACEi and ARB does not increase strokes or alter other major cardiovascular or renal events in patients with diabetes, irrespective of the presence of nephropathy.
authors.affiliation: Munich General Hospitals, Munich and Friedrich Alexander University, Erlangen-Nuremberg, Germany. johannes.mann@kms.mhn.de
authors.forename: Johannes F E
authors.initials: JF
authors.lastname: Mann
authors.forename: Craig
authors.initials: C
authors.lastname: Anderson
authors.forename: Peggy
authors.initials: P
authors.lastname: Gao
authors.forename: Hertzel C
authors.initials: HC
authors.lastname: Gerstein
authors.forename: Michael
authors.initials: M
authors.lastname: Boehm
authors.forename: Lars
authors.initials: L
authors.lastname: Rydén
authors.forename: Peter
authors.initials: P
authors.lastname: Sleight
authors.forename: Koon K
authors.initials: KK
authors.lastname: Teo
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000453:epidemiology*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors